268 related articles for article (PubMed ID: 31882545)
1. Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Peluso G; Tian E; Abusleme L; Munemasa T; Mukaibo T; Ten Hagen KG
J Biol Chem; 2020 Jan; 295(5):1411-1425. PubMed ID: 31882545
[TBL] [Abstract][Full Text] [Related]
2. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
Ichikawa S; Sorenson AH; Austin AM; Mackenzie DS; Fritz TA; Moh A; Hui SL; Econs MJ
Endocrinology; 2009 Jun; 150(6):2543-50. PubMed ID: 19213845
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ; Imel EA
Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
[TBL] [Abstract][Full Text] [Related]
6. A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.
Esapa CT; Head RA; Jeyabalan J; Evans H; Hough TA; Cheeseman MT; McNally EG; Carr AJ; Thomas GP; Brown MA; Croucher PI; Brown SD; Cox RD; Thakker RV
PLoS One; 2012; 7(8):e43205. PubMed ID: 22912827
[TBL] [Abstract][Full Text] [Related]
7. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
Vieira AR; Lee M; Vairo F; Loguercio Leite JC; Munerato MC; Visioli F; D'Ávila SR; Wang SK; Choi M; Simmer JP; Hu JC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):e235-9. PubMed ID: 26337219
[TBL] [Abstract][Full Text] [Related]
8. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
[TBL] [Abstract][Full Text] [Related]
9. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.
Topaz O; Shurman DL; Bergman R; Indelman M; Ratajczak P; Mizrachi M; Khamaysi Z; Behar D; Petronius D; Friedman V; Zelikovic I; Raimer S; Metzker A; Richard G; Sprecher E
Nat Genet; 2004 Jun; 36(6):579-81. PubMed ID: 15133511
[TBL] [Abstract][Full Text] [Related]
10. GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Chefetz I; Kohno K; Izumi H; Uitto J; Richard G; Sprecher E
Biochim Biophys Acta; 2009 Jan; 1792(1):61-7. PubMed ID: 18976705
[TBL] [Abstract][Full Text] [Related]
11. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.
Chefetz I; Sprecher E
Biochim Biophys Acta; 2009 Sep; 1792(9):847-52. PubMed ID: 19013236
[TBL] [Abstract][Full Text] [Related]
12. A novel
Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
[TBL] [Abstract][Full Text] [Related]
13. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Ichikawa S; Gray AK; Padgett LR; Allen MR; Clinkenbeard EL; Sarpa NM; White KE; Econs MJ
Endocrinology; 2014 Oct; 155(10):3891-8. PubMed ID: 25051439
[TBL] [Abstract][Full Text] [Related]
14. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
Ito N; Fukumoto S
Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
[TBL] [Abstract][Full Text] [Related]
15. Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
Albaramki J; Dmour H; Shboul M; Bonnard C; Venkatesh B; Odeh R
Turk J Pediatr; 2019; 61(1):130-133. PubMed ID: 31559735
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
Mahjoubi F; Ghadir M; Samanian S; Heydari I; Honardoost M
J Endocrinol Invest; 2020 Aug; 43(8):1125-1130. PubMed ID: 32125652
[TBL] [Abstract][Full Text] [Related]
17. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
Frishberg Y; Ito N; Rinat C; Yamazaki Y; Feinstein S; Urakawa I; Navon-Elkan P; Becker-Cohen R; Yamashita T; Araya K; Igarashi T; Fujita T; Fukumoto S
J Bone Miner Res; 2007 Feb; 22(2):235-42. PubMed ID: 17129170
[TBL] [Abstract][Full Text] [Related]
18. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
[TBL] [Abstract][Full Text] [Related]
19. GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis.
Demellawy DE; Chang N; de Nanassy J; Nasr A
Scand J Rheumatol; 2015; 44(2):170-2. PubMed ID: 25351881
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]